|
Bertis Launches Pan-omics Analysis Solution ‘PASS’ to Mark Business Expansion from Diagnostics to Analytics
- PASS is an integrative analysis solution based on pan-omics and bioinformatics technology necessary for clinical research to develop novel drugs such as individualized therapies and exosome therapies - Bertis has professional scientists and cutting-edge analysis equipment to ensure integrative services from sample analysis to result interpretation and visualization - PASS is the second commercialized product from Bertis following its world-first proteomic-based breast cancer blood test solution MASTOCHECK®, the launch marks business expansion from diagnostics to analytics .jpg)
May 26, 2022, SEOUL, KOREA -- Bertis Inc., a South Korean biotech company dedicated to proteomic-based precision medicine, today announced the official release of PASS, an integrative analysis solution of pan-omics. Pan-omics is a biological analysis approach where the data sets are multiple “omes”, such as the proteome, metabolome, and genome. This approach draws attention globally as a strategy to better understand disease diagnosis and treatment. Based on Bertis’ pan-omics and bioinformatics technology, PASS (Pan-omics Analysis Service & Solution) provides a necessary analysis solution not only the protein analysis and biomarker discovery but also the clinical research to develop novel drugs such as individualized therapies and exosome therapies.-
- PASS, which goes beyond the analysis of samples, encompasses all research processes, including data interpretation and visualization of analysis results. PASS consists of four major services as follows:
- GP-PASS, a proteomic analysis service based on mass spectrometry and algorithms - CDx-PASS, a companion diagnostic solution for clinical research of individualized therapies - Exo-PASS, an all-in-one package solution optimized for R&D of exosome therapies - PC-PASS, an individualized solution for the development of biologic therapies
“Demand for professional analysis services for clinical trial data is on the rise from the pharmaceutical and biotech industry as the systematic analysis of such data is becoming increasingly critical to improving the efficiency and success in drug development,” said Un-beom Kang, head of Bertis biomarker research institute. “As a leader in the field of proteomics and bioinformatics in Korea, we are aiming to further enhance analytics capabilities of domestic clinical trial data through PASS and contribute to the development of innovative therapeutics in Korea.” Bertis has industry-leading know-how for pan-omics analysis and a lineup of cutting-edge analysis tools, which are built on over 10 years of proteomics research. This paved the way for the company’s world-first commercialization of proteomic-based breast cancer blood test solution MASTOCHECK®, which was authorized by the Ministry of Food and Drug Safety in 2019. MASTOCHECK is available at more than 100 hospitals and health clinics nationwide as of May. “The launch of PASS marks a new milestone in the expansion of our business from diagnostics to analytics for discovery of potential therapeutic targets,” said Seung-man Han, chief executive officer of Bertis. “We expect to be able to further contribute to a healthier future by developing business based on our proprietary technology and know-how and advancing the field of precision medicine.” Bertis provides a web page for information on PASS services with a Q&A option. For more, please visit the official company website (http://bertis.com/product/pass.asp).
|
